ERNA Ernexa Therapeutics Inc.
Price Chart
Executive Summary
Ernexa Therapeutics announced preclinical data showing its lead cell therapy candidate ERNA-101, combined with PD-1 blockade, achieved complete tumor clearance and 100% long-term survival in ovarian cancer models. The company plans to advance ERNA-101 toward a first-in-human clinical trial in advanced ovarian cancer. With a $5M market cap and no revenue, this is an early-stage, high-risk binary event with no near-term catalyst date.
Actionable Insight
This is an early preclinical data release with no near-term catalyst date. The stock may see speculative movement, but the lack of a concrete clinical timeline or regulatory milestone limits actionable trading. Monitor for updates on IND filing or partnership announcements.
Key Facts
- ERNA-101 in combination with anti-PD-1 therapy achieved complete tumor clearance and 100% survival in syngeneic ovarian cancer models.
- Data demonstrate tumor microenvironment remodeling from immunosuppressive to immune-activated.
- Company plans to incorporate findings into development strategy toward first-in-human clinical trial in advanced ovarian cancer.
- No specific timeline, financial data, or regulatory milestone dates provided.
- Market cap is $5M with no revenue; company is pre-commercial with no approved products.
Financial Impact
No financial figures disclosed; preclinical data only.
Risk Factors
- Preclinical results may not translate to human clinical trials.
- No timeline for first-in-human trial initiation.
- Company has no revenue and limited cash runway (not disclosed).
- Ovarian cancer is a competitive space with many failed therapies.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288833 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
13d ago
|
Press Release
| $11.14 $8.00 | ▼ −28.19% | ▼ −29.39% | $6.80 (−38.96%) |
|
May 6, 2026
4w ago
|
Press Release
| $6.04 $12.01 | ▲ +98.84% | ▲ +97.71% | $6.80 (+12.58%) |
|
Mar 31, 2026
10w ago
|
Press Release
| $5.00 $0.2200 | ▼ −95.60% | ▼ −99.54% | $6.80 (+36.00%) |
|
Mar 24, 2026
11w ago
|
S-3/A
| $5.25 $0.2100 | ▲ +96.00% | ▲ +95.76% | $6.80 (−29.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access